Cargando…
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. PD-1...
Autores principales: | Yang, Tinglin, Li, Wenhui, Huang, Tao, Zhou, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055616/ https://www.ncbi.nlm.nih.gov/pubmed/36983708 http://dx.doi.org/10.3390/jpm13030526 |
Ejemplares similares
-
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022) -
Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
por: Nakhjavani, Maryam, et al.
Publicado: (2022) -
Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022) -
PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023) -
Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)